Respiratory controversies in the critical care setting. When caring for critically ill patients, do clinicians have a responsibility to be innovative and try unproven approaches when accepted approaches are failing?
暂无分享,去创建一个
[1] Jerome W. Yates. Food and Drug Administration, Partner in Drug Development , 2006, Ca.
[2] S. Okie. Access before approval--a right to take experimental drugs? , 2006, The New England journal of medicine.
[3] P. Barach,et al. Five System Barriers to Achieving Ultrasafe Health Care , 2005, Annals of Internal Medicine.
[4] J. Grimshaw,et al. From best evidence to best practice: effective implementation of change in patients' care , 2003, The Lancet.
[5] G. Rubenfeld,et al. Understanding why we agree on the evidence but disagree on the medicine. , 2001, Respiratory care.
[6] J. Gray,et al. Evidence-Based Healthcare: How to Make Health Policy and Management Decisions , 2001 .
[7] L. Thompson. Experimental treatments. Unapproved but not always unavailable. Last option for the desperately ill. , 2000, FDA consumer.
[8] A. Guberman. Evidence-Based Healthcare: How to Make Health Policy and Management Decisions , 1997 .
[9] D. Sackett,et al. Evidence based medicine: what it is and what it isn't , 1996, BMJ.
[10] Jocco D. Bailey,et al. Carlton Johnson, et al., v. Webb Thompson, M.D., et al. Petition for a Writ of Certiorari to the United States Court of Appeals for the Tenth Circuit. , 1993, Issues in law & medicine.